子宫内膜癌三级预防策略中国专家共识(2025年版)

中国妇幼健康研究会妇产科精准医疗专业委员会, 上海市医学会妇科肿瘤学分会

中国实用妇科与产科杂志 ›› 2025, Vol. 41 ›› Issue (10) : 1004-1011.

PDF(1272 KB)
PDF(1272 KB)
中国实用妇科与产科杂志 ›› 2025, Vol. 41 ›› Issue (10) : 1004-1011. DOI: 10.19538/j.fk2025100110
专家共识

子宫内膜癌三级预防策略中国专家共识(2025年版)

作者信息 +
文章历史 +

引用本文

导出引用
中国妇幼健康研究会妇产科精准医疗专业委员会, 上海市医学会妇科肿瘤学分会. 子宫内膜癌三级预防策略中国专家共识(2025年版)[J]. 中国实用妇科与产科杂志. 2025, 41(10): 1004-1011 https://doi.org/10.19538/j.fk2025100110
中图分类号: R737.3   

参考文献

[1]
Makker V, MacKay H, Ray-Coquard I, et al. Endometrial cancer[J]. Nat Rev Dis Primers, 2021, 7(1):88. DOI:10.1038/s41572-021-00324-8.
[2]
Gitsch G, Hanzal E, Jensen D, et al. Endometrial cancer in premenopausal women 45 years and younger[J]. Obstet Gynecol, 1995, 85(4):504-508. DOI:10.1016/0029-7844(95)00001-8.
[3]
Wu Y, Sun W, Liu H, et al. Age at menopause and risk of developing endometrial cancer:a meta-analysis[J]. Biomed Res Int, 2019, 2019:8584130. DOI:10.1155/2019/8584130.
[4]
Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States,2019:A review of current American cancer society guidelines and current issues in cancer screening[J]. CA Cancer J Clin, 2019, 69(3):184-210. DOI:10.3322/caac.21557.
[5]
Schmandt RE, Iglesias DA, Co NN, et al. Understanding obesity and endometrial cancer risk:opportunities for prevention[J]. Am J Obstet Gynecol, 2011, 205(6):518-525. DOI:10.1016/j.ajog.2011.05.042.
[6]
Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk,prevention,and treatment[J]. J Clin Oncol, 2016, 34(35):4225-4230. DOI:10.1200/jco.2016.69.4638.
[7]
Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight,obesity,and mortality from cancer in a prospectively studied cohort of U.S. adults[J]. N Engl J Med, 2003, 348(17):1625-1638. DOI:10.1056/NEJMoa021423.
[8]
Lucenteforte E, Bosetti C, Talamini R, et al. Diabetes and endometrial cancer:effect modification by body weight,physical activity and hypertension[J]. Br J Cancer, 2007, 97(7):995-998. DOI:10.1038/sj.bjc.6603933.
[9]
Zhang Y, Liu H, Yang S, et al. Overweight,obesity and endometrial cancer risk:results from a systematic review and meta-analysis[J]. Int J Biol Markers, 2014, 29(1):e21-e29. DOI:10.5301/jbm.5000047.
[10]
Walsh C, Holschneider C, Hoang Y, et al. Coexisting ovarian malignancy in young women with endometrial cancer[J]. Obstet Gynecol, 2005, 106(4):693-639. DOI:10.1097/01.AOG.0000172423.64995.6f.
[11]
Ghanavati M, Khorshidi Y, Shadnoush M, et al. Tamoxifen use and risk of endometrial cancer in breast cancer patients:A systematic review and dose-response meta-analysis[J]. Cancer Rep (Hoboken), 2023, 6(4):e1806. DOI:10.1002/cnr2.1806.
[12]
Lu KH, Schorge JO, Rodabaugh KJ, et al. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer[J]. J Clin Oncol, 2007, 25(33):5158-5164. DOI:10.1200/jco.2007.10.8597.
[13]
Zhao S, Chen L, Zang Y, et al. Endometrial cancer in Lynch syndrome[J]. Int J Cancer, 2022, 150(1):7-17. DOI:10.1002/ijc.33763.
[14]
Moore SC, Lee IM, Weiderpass E, et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults[J]. JAMA Intern Med, 2016, 176(6):816-825. DOI:10.1001/jamainternmed.2016.1548.
[15]
Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society guidelines for the early detection of cancer:update of early detection guidelines for prostate,colorectal,and endometrial cancers. Also:update 2001--testing for early lung cancer detection[J]. CA Cancer J Clin, 2001, 51(1):38-75. DOI:10.3322/canjclin.51.1.38.
[16]
Torgeson A, Boothe D, Poppe MM, et al. Disparities in care for elderly women with endometrial cancer adversely effects survival[J]. Gynecol Oncol, 2017, 147(2):320-328. DOI:10.1016/j.ygyno.2017.08.005.
[17]
Eggemann H, Ignatov T, Burger E, et al. Management of elderly women with endometrial cancer[J]. Gynecol Oncol, 2017, 146(3):519-524. DOI:10.1016/j.ygyno.2017.06.029.
[18]
Bokhman JV. Two pathogenetic types of endometrial carcinoma[J]. Gynecol Oncol, 1983, 15(1):10-17. DOI:10.1016/0090-8258(83)90111-7.
[19]
Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding[J]. Ultrasound Obstet Gynecol, 2004, 24(5):558-565. DOI:10.1002/uog.1704.
[20]
Koskas M, Amant F, Mirza MR, et al. Cancer of the corpus uteri:2021 update[J]. Int J Gynaecol Obstet, 2021, 155(1):45-60. DOI:10.1002/ijgo.13866.
[21]
Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus:a review of their pathology with emphasis on recent advances and problematic aspects[J]. Adv Anat Pathol, 2004, 11(3):117-142. DOI:10.1097/00125480-200405000-00001.
[22]
林奇综合征相关妇科恶性肿瘤综合管理中国专家共识制定专家组. 林奇综合征相关妇科恶性肿瘤综合管理中国专家共识(2025年版)[J]. 肿瘤学杂志, 31(1):2-14. DOI:10.11735/j.issn.1671-170X.2025.01.B001.
[23]
俞梅, 向阳, 马晓欣, 等. 子宫内膜癌筛查规范建议[J]. 中华妇产科杂志, 2020, 55(5):307-311. DOI:10.3760/cma.j.cn112141-20200201-00070.
[24]
Huang RL, Su PH, Liao YP, et al. Integrated epigenomics analysis reveals a DNA methylation panel for endometrial cancer detection using cervical scrapings[J]. Clin Cancer Res, 2017, 23(1):263-272. DOI:10.1158/1078-0432.Ccr-16-0863.
[25]
Liew PL, Huang RL, Wu TI, et al. Combined genetic mutations and DNA-methylated genes as biomarkers for endometrial cancer detection from cervical scrapings[J]. Clin Epigenetics, 2019, 11(1):170. DOI:10.1186/s13148-019-0765-3.
[26]
Fadare O, Liang SX, Ulukus EC, et al. Precursors of endometrial clear cell carcinoma[J]. Am J Surg Pathol, 2006, 30(12):1519-1530. DOI:10.1097/01.pas.0000213296.88778.db.
[27]
Ryan AJ, Susil B, Jobling TW, et al. Endometrial cancer[J]. Cell Tissue Res, 2005, 322(1):53-61. DOI:10.1007/s00441-005-1109-5.
[28]
中华预防医学会生殖健康分会. 子宫内膜癌诊治微创无瘤防御管理指南(2025年版)[J]. 中国实用妇科与产科杂志, 2025, 41(9):905-913. DOI:10.19538/j.fk2025090111.
[29]
Santin AD. HER2/neu overexpression:has the Achilles' heel of uterine serous papillary carcinoma been exposed?[J]. Gynecol Oncol, 2003, 88(3):263-265. DOI:10.1016/s0090-8258(02)00094-x.
[30]
胡兆星, 张运征, 董莹莹, 等. 人工智能辅助下的子宫内膜癌诊疗新理念与新视角[J]. 中国实用妇科与产科杂志, 2025, 41(8):859-864. DOI:10.19538/j.fk2025080119.
[31]
Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma[J]. Int J Gynecol Cancer, 2021, 31(1):12-39. DOI:10.1136/ijgc-2020-002230.
[32]
Centini G, Colombi I, Ianes I, et al. Fertility sparing in endometrial cancer:Where are we now?[J] Cancers (Basel), 2025, 17(1):112. DOI:10.3390/cancers17010112.
[33]
王益勤, 王建六. 子宫内膜癌患者保留生育功能治疗[J]. 中国实用妇科与产科杂志, 2023, 39(11):1090-1095. DOI:10.19538/j.fk2023110108.
[34]
Xu Z, Yang B, Guan J, et al. Comparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer:a prospective,open-label,randomized controlled phaseⅡtrial[J]. J Gynecol Oncol, 2023, 34(1):e32. DOI:10.3802/jgo.2023.34.e32.
[35]
Randall ME, Filiaci V, McMeekin DS, et al. PhaseⅢtrial:adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer[J]. J Clin Oncol, 2019, 37(21):1810-1818. DOI:10.1200/jco.18.01575.
[36]
Li C, Han Z, Chen L, et al. Guiding adjuvant radiotherapy in stageⅢendometrial cancer:a prognostic model based on SEER[J]. Front Oncol, 2024, 14:1480102. DOI:10.3389/fonc.2024.1480102.
[37]
Wang W, Wang T, Liu Z, et al. Overview of adjuvant radiotherapy on survival,failure pattern and toxicity in stageⅠtoⅡendometrial carcinoma:a long-term multi-institutional analysis in China[J]. BMC Cancer, 2022, 22(1):266. DOI:10.1186/s12885-022-09343-4.
[38]
Gómez-Raposo C, Merino Salvador M, Aguayo Zamora C, et al. Adjuvant chemotherapy in endometrial cancer[J]. Cancer Chemother Pharmacol, 2020, 85(3):477-486. DOI:10.1007/s00280-019-04027-6.
[39]
Prabhu V, Kelkar S, Zhang J, et al. Real-world treatment patterns and clinical outcomes in patients with advanced or recurrent endometrial cancer re-challenged with platinum-based chemotherapy in Europe[J]. Int J Gynecol Cancer, 2025, 35(4):101658. DOI:10.1016/j.ijgc.2025.101658.
[40]
Bogani G, Monk BJ, Powell MA, et al. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer[J]. Ann Oncol, 2024, 35(5):414-428. DOI:10.1016/j.annonc.2024.02.006.
[41]
Fader AN, Roque DM, Siegel E, et al. Randomized phase ⅱ trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu[J]. J Clin Oncol, 2018, 36(20):2044-2051. DOI:10.1200/jco.2017.76.5966.
[42]
Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer:updated efficacy and safety from the randomized phase Ⅲ study 309/keynote-775[J]. J Clin Oncol, 2023, 41(16):2904-2910. DOI:10.1200/jco.22.02152.
[43]
Mestdagh F, Steyaert A, Lavand'homme P. Cancer pain management:a narrative review of current concepts,strategies,and techniques[J]. Curr Oncol, 2023, 30(7):6838-6858. DOI:10.3390/curroncol30070500.
[44]
Stewart AJ, Brooker C, Vose G, et al. Pain and symptom relief using inhaled methoxyflurane for gynecologic brachytherapy applicator removal[J]. J Contemp Brachytherapy, 2023, 15(1):37-42. DOI:10.5114/jcb.2023.125581.
[45]
中国抗癌协会子宫体肿瘤专业委员会, 中国妇产科精准医学协会.子宫内膜癌手术治疗质量控制与评价标准中国专家共识(2024年版)[J]. 中国实用妇科与产科杂志, 2024, 40(6):626-637. DOI:10.19538/j.fk2024060113.
[46]
Deleris R, Bureau C, Lebbah S, et al. Low dose of morphine to relieve dyspnea in acute respiratory failure:the OpiDys double-blind randomized controlled trial[J]. Respir Res, 2024, 25(1):280. DOI:10.1186/s12931-024-02867-2.
[47]
Li R, Liu L, Wei K, et al. Effect of noninvasive respiratory support after extubation on postoperative pulmonary complications in obese patients:A systematic review and network meta-analysis[J]. J Clin Anesth, 2023, 91:111280. DOI:10.1016/j.jclinane.2023.111280.
[48]
Dave S, Patel B. The lipocalin saga:Insights into its role in cancer-associated cachexia[J]. Biochim Biophys Acta Mol Basis Dis, 2025, 1871(3): 167684. DOI:10.1016/j.bbadis.2025.167684.
[49]
Wang Y, Wei W, Wang Y, et al. Innovative applications of medium- and long-chain triacylglycerol in nutritional support:Current perspectives and future directions[J]. Compr Rev Food Sci Food Saf, 2025, 24(2):e70116. DOI:10.1111/1541-4337.70116.
[50]
Nephew LD, Moore C, Garcia N, et al. Information overload,financial constraints,and psychological burdens are among the barriers faced by marginalized groups seeking curative treatments for HCC[J]. Hepatol Commun, 2025, 9(3):e0660. DOI:10.1097/hc9.0000000000000660.
[51]
Bowers M, Petrasso C, McLuskie A, et al. Multicomponent interventions for adults with cancer cachexia:a systematic review[J]. J Cachexia Sarcopenia Muscle, 2025, 16(2):e13716. DOI:10.1002/jcsm.13716.
[52]
Martina D, Kustanti CY, Dewantari R, et al. Advance care planning for patients with cancer and family caregivers in Indonesia:a qualitative study[J]. BMC Palliat Care, 2022, 21(1):204. DOI:10.1186/s12904-022-01086-0.
[53]
Leitch M, Arshad A, Cohen PA, et al. Patient-initiated follow-up in low-risk endometrial cancer after surgery:a systematic review[J]. Int J Gynecol Cancer, 2025, 35(2):100037. DOI:10.1016/j.ijgc.2024.100037.
[54]
Abu-Rustum N, Yashar C, Arend R, et al. Uterine Neoplasms,Version 1.2023,NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2023, 21(2):181-209. DOI:10.6004/jnccn.2023.0006.
[55]
Bergerot CD, Philip EJ, Bergerot PG, et al. Fear of cancer recurrence or progression:what is it and what can we do about it[J]. Am Soc Clin Oncol Educ Book, 2022, 42:1-10. DOI:10.1200/edbk_100031.
[56]
Choi Y, Radhakrishnan A, Mahabare D, et al. The johns hopkins primary care for cancer survivor clinic:lessons learned in our first 4 years[J]. J Cancer Surviv, 2020, 14(1):19-25. DOI:10.1007/s11764-019-00816-3.
[57]
曹瑢, 陈刚. 卵巢恶性肿瘤随访[J]. 中国实用妇科与产科杂志, 2024, 40(11):1091-1093.DOI:10.19538/j.fk2024110109.
[58]
Peng L, Liao Y, Zhou R, et al. FDG PET/MRI combined with chest HRCT in early cancer detection:a retrospective study of 3020 asymptomatic subjects[J]. Eur J Nucl Med Mol Imaging, 2023, 50(12):3723-3734. DOI:10.1007/s00259-023-06273-6.
[59]
Mili N, Paschou SA, Goulis DG, et al. Obesity,metabolic syndrome,and cancer:pathophysiological and therapeutic associations[J]. Endocrine, 2021, 74(3):478-497. DOI:10.1007/s12020-021-02884-x.
[60]
庞晓燕, 张颐. 子宫颈癌患者的营养管理[J]. 中国实用妇科与产科杂志, 2024, 40(1):35-38.DOI:10.19538/j.fk2024010110.
[61]
Ma Z, Ma R. Designing cancer warning labels for alcoholic beverages:examining the impact of visual elements[J]. Health Educ Behav, 2023, 50(5):586-594. DOI:10.1177/10901981231166696.
[62]
谢玲玲, 林仲秋. 《国际妇产科联盟(FIGO)2025癌症报告:子宫内膜癌诊治指南》更新解读[J]. 中国实用妇科与产科杂志, 2025, 41(9):928-935. DOI:10.19538/j.fk2025090114.
[63]
衣磊, 马德花, 崔竹梅. 子宫颈癌患者的心理治疗[J]. 中国实用妇科与产科杂志, 2024, 40(1):32-35.DOI:10.19538/j.fk2024010109.

基金

国家自然科学基金(82273233)
上海市科委项目(22ZR1408900)
上海市科委项目(25Y22800300)
上海申康医院发展中心项目(SHDC22021307)
上海申康医院发展中心项目(SHDC22024218)
上海申康医院发展中心项目(SHDC22024303)
上海申康医院发展中心项目(SHDC2020CR4079)
上海申康医院发展中心项目(SHDC22025206)

PDF(1272 KB)

Accesses

Citation

Detail

段落导航
相关文章

/